TTrialPathMatch Me to Trials
← Back to trials
RecruitingChronic Lymphocytic LeukemiaLymphomas Non-Hodgkin's B-CellLymphoma, Small Lymphocytic

Long-term Follow-up Study of Patients Receiving CAR-T Cells

Eligible age

18–80 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This protocol is designed as a long-term follow-up study of participants who will receive CAR-T cells as part of a clinical trial at the Medical College of Wisconsin/ Froedtert Hospital. The clinical trials include the following: Phase 1 Study of CAR-20/19-T Cells in Patients with Relapsed Refractory B Cell Malignancies (NCT03019055); Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma (NCT05976555); CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies (NCT05094206); LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies (NCT05990465); CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies (NCT04186520)

Sponsor: Medical College of Wisconsin

You may qualify if…

  • ✓ All participants who enrolled in a CAR-T study at Froedtert Hospital \& the Medical College of Wisconsin.

You may not qualify if…

  • ✕ There are no exclusion criteria for this study.

Where it's recruiting

Wisconsin

Milwaukee

Source: ClinicalTrials.gov · NCT03375619 · last updated 2025-11-10

Long-term Follow-up Study of Patients Receiving CAR-T Cells · TrialPath